Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

Aryeh Fischer, MD, and Jeff Swigris, DO, MS  |  Issue: December 2012  |  December 1, 2012

Interstitial lung disease (ILD) refers to a large group of diffuse parenchymal lung disorders characterized histologically by inflammation, fibrosis, or a combination of the two (see Table 1). Common causes of ILD include exposure to environmental antigens (e.g., avian proteins) or occupational dusts (e.g., silica or asbestos), and ILD is a common lung manifestation of connective tissue disease (CTD). Although ILD may result from any of the classifiable CTDs, patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing CTD-associated ILD (CTD-ILD). There is growing appreciation that ILD may be the first manifestation of a CTD; in fact, some experts believe that ILD may be the only manifestation of a CTD.1 In this report, we aim to discuss the epidemiology, classification, and clinical features of CTD-ILD and to highlight some areas of uncertainty and gaps in our understanding of this condition.

Prevalence of CTD-ILD

The true incidence and prevalence of ILD occurring in association with CTD are unknown. Published estimates vary because of differences in study design, in particular how cohorts are identified and the methods used to define the presence of ILD. For example, investigators who use autopsy data to confirm the presence of ILD undoubtedly overestimate the prevalence of clinically significant ILD. Prevalence estimates for CTD-ILD range from 25–90% for SSc, from 5–70% for PM/DM, from 2–63% for RA, from 8–38% for Sjögren’s disease, and from 3–38% for systemic lupus erythematosus.2 We believe that clinically significant CTD-ILD probably occurs more commonly than many rheumatologists appreciate, yet less often than pulmonologists believe. Clearly, more research is needed to better understand the epidemiology of CTD-ILD.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

click for large version
Table 1: Classification of ILDs

Classification of CTD-ILD Based on Histopathology

To characterize the histologic patterns in surgical lung biopsy (SLBx) specimens from patients with ILD, including those with CTD-ILD, pathologists use the classification scheme developed for the idiopathic interstitial pneumonias (IIPs).3 The IIPs are a group of seven ILDs of unknown cause, with potentially overlapping clinical and radiological features but different prognoses (see Table 1). Over the years, a challenging nomenclature and ever-changing classification scheme has created confusion around the IIPs. Also clouding understanding is the fact that, although the seven histologic patterns decisively distinguish one IIP from another, the patterns are not specific to “idiopathic” disease and may occur in ILD of any cause. For example, the fibrotic pattern of usual interstitial pneumonia (UIP pattern) has a number of potential causes, including chemotherapy-induced ILD, hypersensitivity pneumonitis, sarcoidosis, or any of the CTDs. The UIP pattern is the most common histological pattern in patients with IIP. However, among patients with CTD-ILD who undergo SLBx, the pattern of nonspecific interstitial pneumonia (NSIP pattern) is most frequently identified. It is unclear whether the NSIP pattern appears to predominate because of significant selection bias: relatively few patients with CTD-ILD undergo SLBx.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsResearch RheumRheumatoid ArthritisSjögren’s Disease Tagged with:DiagnosisILDimagingInterstitial Lung Diseasepatient careResearchRheumatoid arthritisrheumatologistSjogren'sTreatment

Related Articles

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

    When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

    February 15, 2017

    SAN FRANCISCO—Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation or fibrosis of the lungs. The disorders are also associated with a spectrum of connective tissue diseases (CTDs). ILD is a common manifestation of CTDs, such as scleroderma, poly-/dermatomyositis and rheumatoid arthritis—and is a leading cause of morbidity and mortality in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences